OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.